Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 5/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25275679 | 0.97 | CYP11B2 (0.52) | CYP11B2ACACBUSP2SCD5HDAC2 | |
| SCHEMBL24112531 | 0.95 | CYP11B2 (0.51) | CYP11B2ACACBUSP2SCD5HDAC2 | |
| SCHEMBL6868004 | 0.93 | CYP11B2 (0.54) | CYP11B2ACACBUSP2SCD5HDAC2 | |
| SCHEMBL25052826 | 0.90 | HPGD (0.46) | CYP11B2ACACBUSP2SCD5HDAC2 | |
| SCHEMBL14240265 | 0.90 | HPGD (0.46) | CYP11B2ACACBUSP2SCD5HDAC2 | |
| SCHEMBL20937613 | 0.89 | USP2 (0.53) | CYP11B2USP2SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL18390155 | 0.88 | CYP11B2 (0.51) | CYP11B2ACACBUSP2SCD5HDAC2 | |
| SCHEMBL4271629 | 0.88 | CYP11B2 (0.51) | CYP11B2ACACBUSP2SCD5HDAC2 | |
| SCHEMBL8149066 | 0.88 | HPGD (0.53) | CYP11B2ACACBUSP2SCD5HDAC2 | |
| SCHEMBL16075034 | 0.87 | USP2 (0.46) | CYP11B2ACACBUSP2SCD5HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| CN-120051470-A | Azaquinazoline compounds and methods of use | 依安彼克医疗有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119894880-A | Quinazoline compounds and methods of use | 依安彼克医疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119816496-A | Aromatic acetylene derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-112442050-B | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023109540-A1 | HETEROCYCLIC COMPOUND WITH AKT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-114409656-B | PIM kinase inhibitors | 杭州邦顺制药有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-114409656-A | PIM kinase inhibitors | 杭州邦顺制药有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | CYP11B2 3429/4885ACACB 1599/4885USP2 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.